Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04475549 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
A Phase 2 study, sponsored by Tisento Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04475549 is a Phase 2 study that was terminated before completion, run by Tisento Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT04475549, a Phase 2 study, was terminated before completion, sponsored by Tisento Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
Interventions
- DRUG IW-6463 Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2022-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04475549
The ClinicalTrials.gov registry entry for NCT04475549 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tisento Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IW-6463 Tablets is the first listed.
NCT04475549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04475549 about?
NCT04475549 is a clinical study titled "Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)". This is a single-arm study to evaluate safety and tolerability of oral IW-6463 in adults diagnosed with MELAS.
What is the current status of trial NCT04475549?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-11-13. Estimated completion is 2022-01-23.
What interventions are being tested in trial NCT04475549?
The interventions under investigation include: IW-6463 Tablets (DRUG).
Who is sponsoring clinical trial NCT04475549?
This trial is sponsored by Tisento Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.